It was a breakthrough moment: the recent announcement that a new Alzheimer’s drug, the first for 20 years, has been approved for use in America. John Hardy, the scientist behind it, speaks about what the development means for people who have the disease.
Almost four decades ago a desperate woman sent John Hardy a letter.
“Dear Sir,” Carol Jennings, from Nottingham in England, wrote in her careful handwriting. “I was very interested to read of your research in the Alzheimer’s Disease Society News and think my family could be of use.”